In Vitro Metabolic and Mitogenic Signaling of Insulin Glargine and Its Metabolites
Mark R. Sommerfeld, Günter Müller, Georg Tschank et al. · 2010
Read In Vitro Metabolic and Mitogenic Signaling of Insulin Glargine and Its Metabolites by Mark R. Sommerfeld, Günter Müller, Georg Tschank et al. (2010) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/plos-pone-0009540.txt.
Description
Mark Sommerfeld and colleagues examined a long acting insulin in the lab in PLOS ONE in 2010. Insulin glargine, sold as Lantus, gives people with diabetes steady sugar control for a full day. After injection under the skin, part of it is changed into two breakdown products. The team studied how the drug and those products signal inside cells.
They separated signals that handle sugar from signals that push cell growth. The products behaved much like the parent drug in these tests. That detail matters, because growth signals have raised safety questions for insulins. Knowing exactly what circulates and acts helps doctors judge the drug's long term use.
Catalog record
| CREATOR | Mark R. Sommerfeld, Günter Müller, Georg Tschank et al. |
|---|---|
| YEAR | 2010 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 47 KB |
| LICENSE | Creative Commons Attribution License |
| RIGHTS | CC BY |
| SOURCE | PLOS ONE |
Source: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0009540